Tirzepatide injection uses: the evidence and the licence

What the trial data says about tirzepatide's two licensed uses

The evidence base for tirzepatide splits cleanly along its two licensed indications. For weight management, the SURMOUNT programme provided the pivotal data: SURMOUNT-1 randomised 2,539 adults with obesity or overweight plus at least one weight-related condition (none had type 2 diabetes) and followed them for 72 weeks. At the 15 mg dose, average body-weight reduction was around 20–21%, a figure that established tirzepatide as among the most effective medicines in this class. NICE cited this evidence in its December 2024 appraisal of tirzepatide (TA1026), recommending it for adults with a BMI of 35 or above and at least one weight-related comorbidity on the NHS, though private eligibility, set by the licensed SmPC, starts at a BMI of 30.

For type 2 diabetes, the SURPASS trials demonstrated meaningful reductions in HbA1c alongside weight loss, leading to a separate MHRA licence for that indication. The mechanism is the same in both settings: tirzepatide activates GIP and GLP-1 receptors together, slowing gastric emptying, reducing appetite and improving insulin sensitivity. That dual action is what sets it apart from singlereceptor GLP-1 medicines.

One note that comes up often in clinical practice: the weight-loss licence and the diabetes licence overlap in some patients, and if you want a fuller picture of what mounjaro injection uses are covered under each indication, that page works through both in detail. People with type 2 diabetes and obesity may be eligible under either indication, and which applies will shape the NHS vs private route available to them. A prescriber works through that picture as part of the assessment.

Which injection sites are used, and how the pen is designed

The tirzepatide KwikPen delivers a once-weekly subcutaneous injection into one of three approved sites: the abdomen, the thigh, or the upper arm. Rotating between these sites from week to week helps avoid localised skin reactions. Each pre-filled pen contains four weekly doses, so one pen covers a full month of treatment at a given strength.

The pen is designed for self-injection and does not require a separate needle to be attached before use, though a question our prescribers hear most weeks is whether the needles can be changed between doses for hygiene. The short answer is yes, and it's good practice; if you need replacement needles, compatible needles are available separately. For anyone who wants to understand the gauge and length specifications before ordering, our tirzepatide injection needle page covers the compatible options and what to look for. The full injection technique (including how to prime the pen, the correct angle, and what to do with used equipment) is covered step by step on the tirzepatide injection technique page, and the patient information leaflet that comes with the pen is the definitive reference for anything specific to your prescription.

Storage matters too. If you would like a closer look at the device itself before starting treatment, the tirzepatide pen page explains how the KwikPen is constructed and how each dose mechanism works. The pen is refrigerated between 2°C and 8°C. For the precise room-temperature window if you need to travel or if the pen has been out of the fridge, always check the leaflet rather than relying on general guidance, that window is set by the manufacturer and confirmed in the SmPC.

Side effects tied to how tirzepatide is used

The most commonly reported side effects from tirzepatide injections are gastrointestinal: nausea, loose stools, constipation, reflux and burping. These tend to be at their most noticeable in the first few weeks after starting or following a dose increase, and they usually settle as the body adjusts. They are also the main reason the licensed schedule begins at 2.5 mg, that starting dose exists to give the digestive system time to adapt rather than to produce weight loss directly.

More serious but less common effects are worth knowing about. The MHRA issued a Drug Safety Update in January 2026 drawing attention to acute pancreatitis as an infrequent but potentially serious side effect of GLP-1 class medicines: severe, persistent stomach pain that may travel through to the back, with or without vomiting, warrants urgent medical attention. Gallbladder symptoms (upper-right abdominal pain, fever) and signs of dehydration from prolonged vomiting or diarrhoea are also reasons to contact a doctor promptly rather than waiting it out.

The NHS medicines page for tirzepatide has a detailed, up-to-date list of side effects and when to get help, and it's the most practical patient-level reference available. Any suspected adverse reaction can also be reported directly to the MHRA via the Yellow Card scheme, patients can do this themselves, not just clinicians.

Who the injection is and isn't suitable for

The licensed population for tirzepatide's weight-management use covers adults with a BMI of 30 or above, or those with a BMI of 27 or above alongside a qualifying condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease or prediabetes. Lower BMI thresholds apply for certain ethnic backgrounds under UK guidance. That said, BMI alone does not determine suitability. A full clinical picture matters: history of pancreatitis, medullary thyroid carcinoma or the inherited condition MEN2 are among the contraindications a prescriber will screen for.

Tirzepatide is not licensed for anyone under 18. It is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive, and the MHRA advises using effective contraception throughout treatment. Women taking the oral contraceptive pill should know that tirzepatide can reduce pill absorption, adding a non-oral method for the first four weeks of treatment and for four weeks after each dose increase is the practical safeguard NHS guidance recommends.

If you're considering tirzepatide for weight management and want to understand whether you're likely to be eligible, the tirzepatide overview sets out the licensed criteria in full, and the weight-loss treatment page covers how the different options compare. For context on what private treatment currently costs following the supply-chain changes in 2025, the Eli Lilly price increase explainer is worth reading before you compare providers. The only way to know whether tirzepatide is right for you is a proper clinical assessment, if you'd like to start that process, you're welcome to speak to our prescribers.